Se espera que el mercado de la hipertensión arterial pulmonar crezca de 7.369,89 millones de dólares en 2021 a 10.889,08 millones de dólares en 2028; se estima que crecerá a una tasa compuesta anual del 5,8 % de 2022 a 2028.
El mercado de la hipertensión arterial pulmonar está segmentado según el fármaco, el tipo, la vía de administración, el canal de distribución y la geografía. El informe ofrece información y un análisis en profundidad del mercado de la hipertensión arterial pulmonar, enfatizando varios parámetros como la dinámica, las tendencias y las oportunidades del mercado y el análisis del panorama competitivo de los principales actores del mercado en varias regiones. También incluye el análisis de impacto de la pandemia de COVID-19 en el mercado de hipertensión arterial pulmonar en todas las regiones.
Perspectivas estratégicas
Perspectivas del mercado
Aprobaciones crecientes de productos pulmonares Los medicamentos para la hipertensión arterial impulsan el crecimiento del mercado
- En septiembre de 2022, Toray Industries, Inc. recibió la aprobación de la Administración Nacional de Productos Médicos (NMPA) de China para las tabletas Careload para tratar Hipertensión arterial pulmonar (HAP). Careload es una formulación de liberación sostenida de beraprost sódico, un derivado de prostaciclina (PGI2), administrada por vía oral.
- En mayo de 2022, United Therapeutic Corporation recibió la aprobación de la Administración de Medicamentos y Alimentos de EE. UU. (FDA) para Tyvaso DPI (treprostinil). polvo para inhalación para tratar la hipertensión pulmonar asociada con la enfermedad pulmonar intersticial (PH-ILD; Grupo 3 de la OMS) y la hipertensión arterial pulmonar (PAH; Grupo 1 de la OMS) para mejorar la capacidad de ejercicio.
- En noviembre de 2021, la FDA de EE. UU. concedió la aprobación provisional al polvo para inhalación de Yutrepia (treprostinil). Yutrepia está indicado para tratar la HAP y mejorar la capacidad de ejercicio en pacientes adultos con síntomas de clase funcional II-III de la New York Heart Association (NYHA).
- En julio de 2021, The Janssen Pharmaceutical Companies of Johnson & Johnson recibió la aprobación de la FDA para la inyección intravenosa (IV) de UPTRAVI (selexipag) para tratar la HAP; Grupo I de la OMS en pacientes adultos con clase funcional (FC) II-III de la OMS, que temporalmente no pueden recibir terapia oral.
- En agosto de 2021, Aerami Therapeutics, Inc. anunció que la FDA concedió a la empresa huérfana designación del fármaco imatinib para el tratamiento de pacientes con HAP. AER: 901, un producto combinado de fármaco y dispositivo candidato para imatinib inhalado para el tratamiento de la HAP, se encuentra en un ensayo de fase 1 cuya finalización está prevista para finales de 2021.
Las crecientes aprobaciones de medicamentos arteriales pulmonares Los medicamentos para la hipertensión en todo el mundo impulsan el crecimiento del mercado de la hipertensión arterial pulmonar.
Información basada en medicamentos
Basado en los fármacos, el mercado de la hipertensión arterial pulmonar se segmenta en antagonistas de los receptores de endotelina (ERA). ), prostaciclina y análogos de prostaciclina, estimuladores de sGC y tiras reactivas de pde-5. El segmento de prostaciclina y análogos de prostaciclina tuvo la mayor participación de mercado en 2021 y se prevé que registre la CAGR más alta durante 2022-2028. La prostaciclina es una pequeña molécula lipídica eicosanoide, también conocida como prostaglandina I-2 (PGI-2), producida por las células endoteliales y actúa localmente, inhibiendo la activación plaquetaria y provocando vasodilatación. La prostaciclina dilata los vasos sanguíneos, mejora el flujo sanguíneo al prevenir la proliferación de células del músculo liso vascular y previene la coagulación sanguínea al inhibir la agregación plaquetaria. Se han desarrollado análogos de prostaciclina como terapias para la HAP. Los análogos de prostaciclina PAH son formas sintéticas de prostaciclina, una sustancia natural producida en el cuerpo. Los pacientes afectados por HAP tienden a tener niveles reducidos de prostaciclina, lo que provoca constricción de los vasos sanguíneos e hipertensión. Los análogos de prostaciclina PAH complementan el requerimiento e imitan la acción de la prostaciclina natural para reducir la hipertensión pulmonar y reducir los síntomas asociados.
Mercado de hipertensión arterial pulmonar, por fármaco: 2021-2028
Información basada en el tipo
Según el tipo, el mercado de la hipertensión arterial pulmonar se divide en de marca y genéricos. El segmento de marca tuvo una mayor participación de mercado en 2021 y se espera que registre una CAGR más alta durante el período de pronóstico. Una compañía farmacéutica vende un medicamento de marca con un nombre o marca comercial específico y que está protegido por una patente. Los medicamentos de marca pueden estar disponibles con receta o sin receta. Riociguat, vendido bajo la marca Adempas, es el medicamento estimulador de la guanilato ciclasa soluble de Bayer. Se utiliza para tratar dos formas de hipertensión pulmonar: hipertensión pulmonar tromboembólica crónica e hipertensión arterial pulmonar.
Información basada en la vía de administración
Según la vía de administración, la hipertensión arterial pulmonar El mercado está segmentado en oral, intravenoso/subcutáneo e inhalado. El segmento oral tuvo la mayor participación de mercado en 2021 y se prevé que registre la CAGR más alta durante el período de pronóstico. Los agentes administrados por vía oral utilizados para el tratamiento de la HAP sintomática de moderada a grave incluyen sildenafilo y los antagonistas del receptor (ERA) de endotelina (ET), bosentan y sitaxentan (sitaxsentan) y abrisentan oral ERA selectivo del receptor ET(A), con mayor afinidad por el receptor ET que bosentan. Además, los nuevos fármacos orales para el tratamiento de la HAP incluyen macitentan, riociguat y treprostinil. Ambrisentan es un antagonista del receptor de endotelina indicado para el tratamiento de la HAP; Grupo 1 de la OMS y retraso del empeoramiento clínico. En combinación con tadalafilo, ambrisentan está indicado para reducir los riesgos de progresión de la enfermedad y de hospitalización por empeoramiento de la HAP, y para mejorar la capacidad de ejercicio.
Información basada en el canal de distribución
Basado en el canal de distribución , el mercado de la hipertensión arterial pulmonar se segmenta en farmacias y clínicas hospitalarias, farmacias en línea y farmacias minoristas. El segmento de clínicas y farmacias hospitalarias tuvo la mayor participación de mercado en 2021 y se prevé que registre la CAGR más alta durante el período de pronóstico. La farmacia hospitalaria se esfuerza por mantener y mejorar continuamente la gestión de medicamentos y la atención farmacéutica de los pacientes con los más altos estándares en un entorno hospitalario. Los farmacéuticos en este campo son responsables de dispensar medicamentos, realizar pruebas de calidad, formular y reformular formas farmacéuticas, monitorear, informar sobre la seguridad de los medicamentos y preparar presupuestos para los medicamentos.
Los actores del mercado de hipertensión arterial pulmonar adoptan estrategias orgánicas, como el lanzamiento y la expansión de productos, para ampliar su presencia y cartera de productos en todo el mundo y satisfacer la creciente demanda. Las estrategias de crecimiento inorgánico observadas en el mercado son asociaciones y colaboraciones. Estas estrategias de crecimiento han permitido a los actores del mercado expandir sus negocios y mejorar su presencia geográfica. Además, las adquisiciones, asociaciones y otras estrategias de crecimiento ayudan a fortalecer la base de clientes de la empresa y aumentar su cartera de productos.
- En septiembre de 2022, Lupin lanzó Sildenafil para administración oral. suspensión en el mercado estadounidense con la aprobación de la FDA estadounidense. El medicamento es una versión genérica de Revatio para suspensión oral de Viatris Specialty LLC. Sildenafil para suspensión oral trata la HAP.
- En febrero de 2021, Aerami Therapeutics, Inc. firmó un acuerdo de licencia y desarrollo exclusivo con Hangzhou Chance Pharmaceuticals Co. Ltd. (Chance) para desarrollar y comercializar el fármaco de Aerami. Producto candidato de combinación de dispositivos (“AER-901”) para el tratamiento de la HAP en China continental, Hong Kong, Macao y Taiwán. Según el acuerdo, Chance es responsable del desarrollo general y la comercialización de AER-901 para PAH en el territorio.
Perfiles de la empresa
- Johnson & Johnson
- Gilead Sciences Inc
- United Therapeutics Corp
- Bayer AG
- Aerami Therapeutics Holdings Inc
- Bayer AG
- Aerami Therapeutics Holdings Inc
- Bayer AG
- Aerami Therapeutics Holdings Inc ; ;
- Novartis AG
- GSK Plc &n bsp;
- Lupin Ltd
- Pfizer Inc
- Teva Pharmaceutical Industries Ltd.
Report Coverage
Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends
Segment Covered
This text is related
to segments covered.
Regional Scope
North America, Europe, Asia Pacific, Middle East & Africa, South & Central America
Country Scope
This text is related
to country scope.
Frequently Asked Questions
Pulmonary arterial hypertension (PAH) is a rare, progressive disorder characterized by high blood pressure (hypertension) in the lungs' arteries. The increased pressure in the vessels may be caused by an obstruction in the lung's small arteries for various reasons. The exact cause of PAH is unknown, and although treatable, there is no permanent cure for the disease. PAH usually affects women between the ages of 30-60. However, individuals with PAH may go years without a diagnosis, either because the symptoms may be mild, nonspecific, or only present during demanding exercise.
The factors driving the growth of pulmonary arterial hypertension are the growing incidence of pulmonary arterial hypertension and the rising approvals of pulmonary arterial hypertension drugs.
The side effects of drugs used for treating pulmonary arterial hypertension are expected to restrict the pulmonary arterial hypertension market growth during the forecast period.
Pulmonary arterial hypertension majorly consists of the players, such as Johnson & Johnson, Gilead Sciences Inc, United Therapeutics Corp, Bayer AG, Aerami Therapeutics Holdings Inc, Novartis AG, GSK Plc, Teva Pharmaceutical Industries Ltd, Lupin Ltd, and Pfizer Inc.
Based on drugs, the pulmonary arterial hypertension market is segmented into prostacyclin and prostacyclin analogs, endothelin receptor antagonists (ERAs), sGC stimulators, and pde-5 dipsticks. In 2021, the prostacyclin and prostacyclin analogs segment accounted for a larger market share. Also, the same segment is anticipated to register a higher CAGR during the forecast period as the PAH prostacyclin analogs are used as medications to treat pulmonary arterial hypertension (PAH), a condition of high blood pressure in the arteries that carry deoxygenated blood from the heart to the lungs.
The global pulmonary arterial hypertension based on regions is segmented into North America, Europe, Asia Pacific, Middle East & Africa, and South & Central America. In 2021, North America held the largest market share. However, the Asia Pacific region is estimated to grow at the fastest CAGR of 6.5% during the forecast period.
The List of Companies - Butterfly Needles Market
- Johnson & Johnson
- Gilead Sciences Inc
- United Therapeutics Corp
- Bayer AG
- Aerami Therapeutics Holdings Inc
- Novartis AG
- GSK Plc
- Teva Pharmaceutical Industries Ltd
- Lupin Ltd
- Pfizer Inc
The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.
- Data Collection and Secondary Research:
As a market research and consulting firm operating from a decade, we have published and advised several client across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.
Several associations trade associates, technical forums, institutes, societies and organization are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in last 3 years are scrutinized and analyzed to understand the current market trends.
- Primary Research:
The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.
For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.
A typical research interview fulfils the following functions:
- Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
- Validates and strengthens in-house secondary research findings
- Develops the analysis team’s expertise and market understanding
Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:
- Industry participants: VPs, business development managers, market intelligence managers and national sales managers
- Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.
Below is the breakup of our primary respondents by company, designation, and region:
Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.
- Data Analysis:
Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.
- Macro-Economic Factor Analysis:
We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.
- Country Level Data:
Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.
- Company Profile:
The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.
- Developing Base Number:
Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.
- Data Triangulation and Final Review:
The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.
We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.
We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.
Related Reports
Jan 2023
Aquatic Veterinary Market
Size and Forecast (2020 - 2030), Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Type (Diagnostics and Treatments), Species (Fish, Crustaceans, Mollusca, and Others), Disease Source (Bacteria, Viruses, Parasites, and Others), Route of Administration (Water Medication, Medicated Feed, and Others), and Geography (North America, Europe, Asia Pacific, Middle East & Africa, and South & Central America)
Jan 2023
Sickle Cell Disease Treatment Market
Size and Forecasts (2020 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis By Treatment (Generic Drugs and Originators), Route of Administration (Oral and Parenteral), and Distribution Channel (Direct Tender, Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, and Others)
Jan 2023
Malaria and Sickle Cell Disease Treatment Market
Size and Forecasts (2020 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Treatment [Malaria and Sickle Cell Disease (SCD)], Route of Administration (Oral and Parenteral), and Distribution Channel (Direct Tender, Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, and Others)
Jan 2023
Pharmaceutical Contract Sales Organizations Market
Size and Forecasts (2020 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Services (Commercial Services and Non-Commercial Services), Modules (Syndicated Modules and Dedicated Modules), Therapeutic Area (Cardiovascular Disorders, Oncology, Metabolic Disorders, Neurology, Orthopedic Diseases, Infectious Diseases, and Others), End User (Biopharmaceutical Companies and Pharmaceutical Companies), and Geography (North America, Europe, Asia Pacific, Middle East & Africa, and South & Central America)
Jan 2023
Breast Cancer Therapeutics Market
Size and Forecasts (2020 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Drug Therapy [Targeted Drug Therapy (Abemaciclib, Ado-Trastuzumab Emtansine, Palbociclib, Trastuzumab, and Other Target Drug Therapies), Hormonal Drug Therapy (Selective Estrogen Receptor Modulators, Aromatase Inhibitors, and Selective Estrogen Receptor Downregulators), Chemotherapy, and Immunotherapy/Biological Therapy], Breast Cancer Type (Hormone Receptor, HER2+, and Triple-Negative Breast Cancer), Distribution Channel (Hospital Pharmacies, Drug Stores and Retail Pharmacies, and Online Pharmacies), and Geography (North America, Europe, Asia Pacific, Middle East & Africa, and South & Central America)
Jan 2023
Radioactive Tracer Market
Size and Forecast to 2030 - Global Analysis by Tracer Type [Technetium-99m & Tc-97m, Iodine-131, Iron-59, Lutetium-171, Rubidium (Rb-82) Chloride & Ammonia (N-13), Scandium-46, Seaborgium-269, Hassium-269, Gallium Citrate Ga 67, Prostate-Specific Membrane Antigen (PSMA) (Ga-68), FDDNP (F-18) & FDOPA (F-18), Phosphorus-32 & Chromium-51, Thallium-201, F-18 FDG, F-18 FAPI, Ga-68 FAPI, F-18 PSMA, DOTATOC/DOTANOC/DOTATATE (Ga-68), and Others], Test Type (PET, SPECT, and Others), Application (Oncology, Pulmonary, Neurology, Cardiology, and Others) End User (Hospitals & Clinics, Diagnostic Centers, Academic & Research Institutes, And Others), and Geography
Jan 2023
Glioma Treatment Market
Size and Forecasts (2020 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Disease (Astrocytoma, Oligoastrocytoma, and Oligodendroglioma), Treatment Type (Surgery, Chemotherapy, Radiation Therapy, and Others), Grade (Low Grade and High Grade), End User (Hospital & Clinics and Ambulatory Surgical Center), and Geography
Jan 2023
Hyperpigmentation Disorder Treatment Market
Size and Forecast (2020 - 2030), Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Treatment Type (Cosmeceutical, Light or Laser Therapy, Microdermabrasion, Chemical Peels, Cryotherapy, and Others), Condition (Melasma, Solar Lentigines, Post-Inflammatory Hyperpigmentation, and Others), End User (Hospitals, Dermatology Centers, and Others), and Geography (North America, Europe, Asia Pacific, South & Central America, and Middle East & Africa)